Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Morphosys Ag (MOR.D.DX)

Morphosys Ag (MOR.D.DX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Morphosys Ag Semmelweisstrasse 7 Planegg BY 82152 DEU

P: +49 89899270

Description:

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.

Key Statistics

Overview:

Market Capitalization, $K 2,546,001
Shares Outstanding, K 37,663
Annual Sales, $ 238,278 K
Annual Net Income, $ -189,734 K
Last Quarter Sales, $ 59,078 K
Last Quarter Net Income, $ 48,266 K
% of Institutional Shareholders 5.57%

Growth:

1-Year Return 150.18%
3-Year Return 51.96%
5-Year Return 0.00%
5-Year Revenue Growth 25.53%

Per-Share Information:

Most Recent Earnings 1.44 on 05/05/22
Next Earnings Date N/A
Earnings Per Share ttm -5.53
EPS Growth vs. Prev Year 24.89%
Dividend Payout Ratio 0.00%
Most Recent Split 3-1 on 12/23/08

MOR.D.DX Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -183.80%
Return-on-Assets % -8.58%
Profit Margin % -79.63%
Debt/Equity 12.68
Price/Sales 9.73
Price/Cash Flow N/A
Price/Book 51.91
Book Value/Share 1.30
Interest Coverage -0.74
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar